Tenet Healthcare (THC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan Langston from TD Cowen maintained a Buy rating on the stock and has a $175.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ryan Langston has given his Buy rating due to a combination of factors, including Tenet Healthcare’s strong first-quarter performance and strategic focus. The company reported a significant increase in EBITDA, outperforming expectations, which was driven by robust revenue growth, patient acuity, and effective cost management. Despite this outperformance, management decided to maintain their full-year guidance, indicating confidence in their strategic direction.
Additionally, Tenet Healthcare’s focus on mergers and acquisitions, labor recruitment, and investment in high-acuity service lines positions them well for future growth. The company’s involvement with HealthTrust GPO and its strategic supply chain management also mitigate potential risks related to tariffs. These factors, along with a targeted valuation multiple, contribute to a positive outlook and justify the Buy rating.
In another report released on April 11, RBC Capital also reiterated a Buy rating on the stock with a $136.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue